人可溶性白细胞介素-4受体（sIL-4R）基因的克隆表达及白细胞介素-4受体（IL-4R）拮抗剂筛选模型的构建研究
摘要
白细胞介素-4(Interleukin 4，IL-4)作为一种多功能细胞因子在免疫反应中起重要作用。由于IL-4能够调控IgE合成，因此在哮喘等变态性炎症反应中具有关键作用。IL-4通过结合细胞表面的白细胞介素-4受体(IL-4 Receptor，IL-4R)发挥生物学效应。IL-4R是异二聚体复合物，通常由IL-4Rα链与γc(Common γ)链组成。IL-4R复合物中IL-4Rα链对结合IL-4起主导作用。
IL-4Rα链cDNA全长3.6kb，含有一个编码825个氨基酸的开放阅读框架，根据推测其中包括25个信号肽氨基酸，207个细胞因子结合域氨基酸，24个跨膜氨基酸，569个细胞内氨基酸。IL-4Rα链胞外结构域包含有WSXWS模块，是受体结合细胞因子必需的最佳构象。在结合配基后，与IL-4R受体偶联的酪氨酸激酶被激活，从而产生信号传导。由于可溶性IL-4Rα链(Soluble interleukin 4 receptor，sIL-4R)缺少跨膜和胞质内结构域所以它不能诱导细胞内的活化过程，但sIL-4R与IL-4结合的高度特异性和极高的亲和力使它非常适合做为理想的IL-4拮抗剂。重组sIL-4R已进入临床研究，结果显示对哮喘有较好疗效。
本研究以人脐静脉内皮细胞总RNA为模板，通过RT-PCR得到编码IL-4Rα链胞外结构域的基因片段sIL-4R cDNA。测序结果同已知sIL-4R基因编码序列进行比较，发现第148位碱基发生A→G的突变，造成第50位氨基酸Ile突变成为Val，根据文献报道，IL-4R基因序列具有多种单核苷酸多态性(SNP)，其中在IL-4Rα链的胞外区表现为Ile50Val，本实验测序结果同文献报道的sIL-4R基因序列的单核苷酸多态性一致。
将sIL-4R基因片段插入甲醇酵母—大肠杆菌穿梭质粒pPIC9K，构建了重组质粒pPIC9K／sIL-4R，将重组质粒转化至甲醇酵母Pichia pastoris GS115，获得了重组菌株P．pastoris[pPIC9K／sIL-4R]。经SDS-PAGE、Western blot分析显示分子量约为30kD，配基结合(Ligand binding)实验结果表明：Mut~s分泌表达的重组sIL-4R具有配基结合的生物活性。
将sIL-4R基因片段插至含有P_RP_L启动子的温敏型表达载体pBV220，获得重组质粒pBV220／sIL-4R，转化至E．coli DH5α作为宿主进行蛋白表达。经42℃诱导和细胞裂解，重组sIL-4R以包涵体形式表达。
S-PAGE分析表明，表达产物在24kDa处有特异蛋白条带出现，与已知sIL-4R分子量23717.75 Da基本一致，Western bloting及受体配基结合实验显示，重组sIL-4R具有免疫学及与配基结合的生物活性。
利用本实验室构建的链霉菌—大肠杆菌穿梭质粒pSGLgpp作为sIL-4R基因的表达载体。将sIL-4R基因片段插入到质粒pSGLgpp中gpp信号肽编码序列下游，利用gpp信号肽介导sIL-4R分泌表达。重组质粒转化至转化至S．lividans TK24原生质体，获得了重组菌S．lividans[pSGLgpp／sIL-4R]。SDS-PAGE、Western bloting及受体配基结合实验结果表明，重组菌株能分泌表达分子量为23.7kD的重组sIL-4R，表达的sIL-4R具有
Interleukin-4 (IL-4) is a pleiotropic cytokine which plays a pivotal role in shaping immune responses. IL-4 mediates important proinflammatory functions in asthma, including of the IgE isotype switch. IL-4 exerts its biological effects through binding to its receptor (IL-4R) complex. IL-4R complex is heterodimer consist of 7 common chain and IL-4Rα chain which is the high affinity binding subunit.
A full-length 3.6kb sIL-4R cDNA includes an open reading frame encoding 825 amino acids. IL-4Ra chain contains a predicted 25 amino acid signal peptide, 207 amino acid external domain, 24 amino acid transmembrane region, and 569 amino acid cytoplasmic domain. IL-4Ra chain contains a conserved WSXWS motif which is required for maintaining the receptor in a conformation favorable to cytokine binding. After IL-4 binding to IL-4R, the receptor-associated tyrosine kinases were activated for the initiation of signal transduction. Soluble IL-4R lacks the transmemberane and cytoplasmic domains so it cannot induce cellular activation. By acting as a decoy to circulating IL-4 and neutralize its activity, its high specificity and affinity make it ideal as an IL-4 antagonist. Recombinant sIL-4R has been used for clinical research of asthma therapy and the result revealed well therapeutic effect. With RNA extracted from human umbilical vein endothelial cell as the template, the sIL-4R cDNA encoding the extracellular domain of IL-4R a chain was obtained by RT-PCR. The cDNA was cloned into the plasmid pUC18 and sequenced. Compared with the sIL-4R encoding sequence in GENBANK, the result showed that there was a A→G mutation at 148 bp and the mutation caused Ile→Val at 50th amino acid. According to the references, numerous polymorphisms .have been identified in the IL-4R gene and the Ile50Val was similar to the data published.
By inserting sIL-4R cDNA into the shuttle plasmid pPIC9K (Yeast-E.coli) , the recombinant plasmid pPIC9K/sIL-4R was constructed, linearized and transformed into Pichia pastoris GS115 by electroporation. The SDS-PAGE and Western blot alysis showed that the apparent molecular weight of expressed sIL-4R was about 30kD. And the Ligand binding analysis indicated the expressed sIL-4R had the biological activity. The sIL-4R, which had the biological activity, was successfully secretorily expressed in the Pichia pastoris(GS 115) with Mut~s phenotype.
The sIL-4R cDNA was inserted into the temperature-regulated expression vector pBV220 with the PrPl promoters. The recombinant plasmid pBV220/sIL-4R was transformed into E.coli DH5a. After induction at 42°C and cell lysis, the recombinant sIL-4R was expressed in the inclusion body form. SDS-PAGE analysis revealed the recombinant sample exhibited a specific band with a molecular weight of 24kDa similar to 23.7kDa calculated from the amino acid sequence. Western blot and the Ligand binding analysis showed that the expressed sIL-4R had the immunological and ligand binding biological activity. Meanwhile, cloning and expression of sIL-4R gene was carried out in S.lividans TK24. The sIL-4R cDNA was inserted into the downstream of gpp signal peptide of the
IL-4Rα链cDNA全长3.6kb，含有一个编码825个氨基酸的开放阅读框架，根据推测其中包括25个信号肽氨基酸，207个细胞因子结合域氨基酸，24个跨膜氨基酸，569个细胞内氨基酸。IL-4Rα链胞外结构域包含有WSXWS模块，是受体结合细胞因子必需的最佳构象。在结合配基后，与IL-4R受体偶联的酪氨酸激酶被激活，从而产生信号传导。由于可溶性IL-4Rα链(Soluble interleukin 4 receptor，sIL-4R)缺少跨膜和胞质内结构域所以它不能诱导细胞内的活化过程，但sIL-4R与IL-4结合的高度特异性和极高的亲和力使它非常适合做为理想的IL-4拮抗剂。重组sIL-4R已进入临床研究，结果显示对哮喘有较好疗效。
本研究以人脐静脉内皮细胞总RNA为模板，通过RT-PCR得到编码IL-4Rα链胞外结构域的基因片段sIL-4R cDNA。测序结果同已知sIL-4R基因编码序列进行比较，发现第148位碱基发生A→G的突变，造成第50位氨基酸Ile突变成为Val，根据文献报道，IL-4R基因序列具有多种单核苷酸多态性(SNP)，其中在IL-4Rα链的胞外区表现为Ile50Val，本实验测序结果同文献报道的sIL-4R基因序列的单核苷酸多态性一致。
将sIL-4R基因片段插入甲醇酵母—大肠杆菌穿梭质粒pPIC9K，构建了重组质粒pPIC9K／sIL-4R，将重组质粒转化至甲醇酵母Pichia pastoris GS115，获得了重组菌株P．pastoris[pPIC9K／sIL-4R]。经SDS-PAGE、Western blot分析显示分子量约为30kD，配基结合(Ligand binding)实验结果表明：Mut~s分泌表达的重组sIL-4R具有配基结合的生物活性。
将sIL-4R基因片段插至含有P_RP_L启动子的温敏型表达载体pBV220，获得重组质粒pBV220／sIL-4R，转化至E．coli DH5α作为宿主进行蛋白表达。经42℃诱导和细胞裂解，重组sIL-4R以包涵体形式表达。
S-PAGE分析表明，表达产物在24kDa处有特异蛋白条带出现，与已知sIL-4R分子量23717.75 Da基本一致，Western bloting及受体配基结合实验显示，重组sIL-4R具有免疫学及与配基结合的生物活性。
利用本实验室构建的链霉菌—大肠杆菌穿梭质粒pSGLgpp作为sIL-4R基因的表达载体。将sIL-4R基因片段插入到质粒pSGLgpp中gpp信号肽编码序列下游，利用gpp信号肽介导sIL-4R分泌表达。重组质粒转化至转化至S．lividans TK24原生质体，获得了重组菌S．lividans[pSGLgpp／sIL-4R]。SDS-PAGE、Western bloting及受体配基结合实验结果表明，重组菌株能分泌表达分子量为23.7kD的重组sIL-4R，表达的sIL-4R具有
Interleukin-4 (IL-4) is a pleiotropic cytokine which plays a pivotal role in shaping immune responses. IL-4 mediates important proinflammatory functions in asthma, including of the IgE isotype switch. IL-4 exerts its biological effects through binding to its receptor (IL-4R) complex. IL-4R complex is heterodimer consist of 7 common chain and IL-4Rα chain which is the high affinity binding subunit.
A full-length 3.6kb sIL-4R cDNA includes an open reading frame encoding 825 amino acids. IL-4Ra chain contains a predicted 25 amino acid signal peptide, 207 amino acid external domain, 24 amino acid transmembrane region, and 569 amino acid cytoplasmic domain. IL-4Ra chain contains a conserved WSXWS motif which is required for maintaining the receptor in a conformation favorable to cytokine binding. After IL-4 binding to IL-4R, the receptor-associated tyrosine kinases were activated for the initiation of signal transduction. Soluble IL-4R lacks the transmemberane and cytoplasmic domains so it cannot induce cellular activation. By acting as a decoy to circulating IL-4 and neutralize its activity, its high specificity and affinity make it ideal as an IL-4 antagonist. Recombinant sIL-4R has been used for clinical research of asthma therapy and the result revealed well therapeutic effect. With RNA extracted from human umbilical vein endothelial cell as the template, the sIL-4R cDNA encoding the extracellular domain of IL-4R a chain was obtained by RT-PCR. The cDNA was cloned into the plasmid pUC18 and sequenced. Compared with the sIL-4R encoding sequence in GENBANK, the result showed that there was a A→G mutation at 148 bp and the mutation caused Ile→Val at 50th amino acid. According to the references, numerous polymorphisms .have been identified in the IL-4R gene and the Ile50Val was similar to the data published.
By inserting sIL-4R cDNA into the shuttle plasmid pPIC9K (Yeast-E.coli) , the recombinant plasmid pPIC9K/sIL-4R was constructed, linearized and transformed into Pichia pastoris GS115 by electroporation. The SDS-PAGE and Western blot alysis showed that the apparent molecular weight of expressed sIL-4R was about 30kD. And the Ligand binding analysis indicated the expressed sIL-4R had the biological activity. The sIL-4R, which had the biological activity, was successfully secretorily expressed in the Pichia pastoris(GS 115) with Mut~s phenotype.
The sIL-4R cDNA was inserted into the temperature-regulated expression vector pBV220 with the PrPl promoters. The recombinant plasmid pBV220/sIL-4R was transformed into E.coli DH5a. After induction at 42°C and cell lysis, the recombinant sIL-4R was expressed in the inclusion body form. SDS-PAGE analysis revealed the recombinant sample exhibited a specific band with a molecular weight of 24kDa similar to 23.7kDa calculated from the amino acid sequence. Western blot and the Ligand binding analysis showed that the expressed sIL-4R had the immunological and ligand binding biological activity. Meanwhile, cloning and expression of sIL-4R gene was carried out in S.lividans TK24. The sIL-4R cDNA was inserted into the downstream of gpp signal peptide of the
引文
1. Chen HJ, Paul WE, Cultured NK1. 1(+)CD4(+) T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J. Immunol. 1997, 159(5): 2240-2249.
2. Seder RA, Paul WE, Davis MM, Fazekas de St Groth B, The presence of interleukin-4 during in vitro priming determines the lymphokine-producing potential of CD4+ T-cells from T-cell receptor transgenic mice. J. Exp. Med. 1992, 176: 1091-1098.
3. Gascan H, Gauchat JF, Roncarolo MG, Yssel H, Spits H, de Vries JE, Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J. Exp. Med. 1991, 173: 747-750.
4. Sager N, Feldmann A, Schilling G, Kreitsch P, Neumann C, House dust mite-specific T cells in the skin of subjects with atopic dermatitis: frequency and lymphokine profile in the allergen patch test. J. Allergy. Clin. Immynol. 1992, 89: 801-810.
5. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C, Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the Fc epsilonRI, CD40L, IL-4 and IL-13, and can induce IgE synthesis in B cells. J. Clin. Invest. 1997, 99: 1492-1499.
6. Duschl A, Sebald W, Transmembrane and intracellular signalling by interleukin-4: receptor dimerization and beyond. Eur Cytokine. Netw. 1996, 7(1): 37-49.
7. Pritchard MA, Baker E, Whitmore SA, Sutherland GR, Idzerda RL, Park LS, Cosman D, Jenkins NA, Gilbert DJ, Copeland NG, et al, The interleukin-4 receptor gene (IL-4) maps to 16p 11.2-16p 12.1 in human and to the distal region of mouse chromosome 7. Genetics. 1991, 10: 801-806.
8. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA, Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science. 1996, 273: 464-471.
9. Mitsuyasu H, Izuhara K, Mao XQ, Gao PS, Arinobu Y, Enomoto T, Kawai M, Sasaki S, Dake Y, Hamasaki N, Shirakawa T, Hopkin JM, Ile50Val variant of IL-4Ralpha upregulates IgE synthesis and associates with atopic asthma. Nature. Genetics. 1998, 19: 119-120.
10. Barnes PJ, Current Therapy for Asthma. Hansel TT, Barnes PJ (Eds): New Drugs for Asthma, Allergy and COPD. Prog. Respir Resr. 2001, 31: 6-10.
11. Vella A, Teague TK, Ihle J, Kappler J, Marrack P, Interleukin 4(IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-4. J. Exp. Med. 1997, 186: 325-330.
12. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garriso L. Interleukin-4 receptor in moderate atopic asthma: A phase Ⅰ/Ⅱ randomized, placebo-controlled trial. Am. J. Respir. Crit. Care. Med. 1999, 160: 1816-1823.
13. Pollock HW, Ebert CS, Dubin MG, White DR, Prazma J, Pillsbury HC 3rd, The role of??soluble interleukin-4 receptor and interleukin-5 ntibody in preventing late-phase allergy-induced eustachian tube dysfunction. Otolaryngol. Head Neck. Surg. 2002, 127: 169-176.
14. Katakura T, Kobayashi M, Fujita K, Herndon DN, Pollard RB, Suzuki F, A Combination Therapy Using IL-12 and Soluble IL-4 Receptor on Herpes Simplex Virus Type 1 Infection in a Human-SCID Chimera Model of Thermal Injury. Clin. Immunol. 2002, 105: 363-370.
15. Jung T, Wagner K, Neumann C, Heusser CH. Enhancement of human IL-4 activity by soluble IL-4 receptors in vitro. Eur. J. Immunol. 1999, 29: 864-871.
16. Idzerda RL, March CJ, Mosley B, Lyman SD, Bos TV, Gimple SD, Din WS, Grabstein KH, Widmer MB, Park LS, Cosman D, Beckmann MP, Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J. Exp. Med 1990, 171: 861-873.
17. Sambrook J, Fritsch EF, Maniatis T, Molecular cloning, A Laboratory Manual, 2nd ed, Cold Spring Harbor Laboratory Press, 1989.
18．霍普伍德等著，邓子新，唐纪良译链霉菌操作手册，湖南科学技术出版社．
19. Zhang Zhiqing, Yao Lihong, Hou Yunde, Construction and application of a high level expression vector containing P_RP_L promoter. Chinese. Journal of Virology. 1990, 6: 111-116.
20. Cregg JM, Cereghino JL, Shi J, Higgins DR, Recombinant protein expression in Pichia pastoris. Molecular Biotechinology. 2000, 16: 23-52.
21. Bochkov VN, Tkachuk VA, Philippova MP, Stambolsky DV, Buhler FR, Resink TJ, Ligand selectivity of 105kD and 130kD lipoprotein-binding proteins in vascular-smooth-muscle-cell membranes is unique. Biochem. J. 1996, 317: 297-304.
22. Bradford MM, McRorie RA, Williams WL, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254.
23. Klaus D, Jurgen B, Johannes F, Andrea H, Joachim K, Common Polymorphisms in the Coding Part of the IL4-Receptor gene. Biochemical And Biophysical Research Communications. 1997, 231: 696-697.
24. Hitzeman RA, Hagie FE, Levine HL, Goeddel DV, Ammerer G, Hall BD, Expreession of a human gene for interferon inyeast. Nature. 1981, 293: 717-722.
25. Clare JJ, Rayment FB, Ballantine SP, Sreekrishna K, Romanos MA, High-level expression of tetanus toxin frangment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Bio/Technology. 1991, 9: 455-460.
26. Rosenfeld SA, Nadeau D, Tirado J, Hollis GF, Knabb RM, Jia S, Production and purification of recombinant hirudin expresses in the methylotrophic yeast Pichia pastoris. Protein. Expr. Purer. 1996, 8: 476-482.
27. Kukuruzinska MA, Bergh MLE, Jackson BJ, Protein glycosylation in yeast. Ann. Rev. Biochem. 1987, 56: 915-955.
28. Romanos MA, Scorer CA, Clare JJ, Foreign gene expression in yeast: a review. Yeast.??1992．8：423-488．
29．张华，中国协和医科大学博士毕业论文，1999，6．
30. Mezes PSE Lampen JO, Secretion of proteins by bacilli. In Dubnau D (Ed.), The Molecular Biology of the Bacilli. Acadamic Press, New York, 1985, 151-183.
31. Monlnar I, Murooka Y, Imanaka T, Recombinant Microbes for Industrial and Agricultural Applications. New York: Maecel Dekker Inc, 1994, 81-104.
32. Gilbert M, Morosoli R, Shareck F, Kluepfel D, Production and secretion of proteins by streptomycetes. Crit. Rev. Biotechnol. 1995, 15(1): 13-39.
33. Binnie C, Cossar J D, Stewart D I, Heterologous biopharmaceutical protein expression in streptornyces. Trends. Biotech. 1997, 15: 315-320.
34. Shen BJ, Hage T, Sebald W, Global and local determinants for the kinetics of interleukin-4/interleukin-4 receptor α chain interaction: A biosensor study employing recombinant interleukin-4-binding protein. Eur. J. Biochem. 1996, 240: 251-261.
35. Binnie C, Jenish D, Cossar D, Szabo A, Trudeau D, Krygsman E Malek LT, Stewart DI, Expression and characterization of soluble human erythropoietin receptor made in Streptomyces lividans 66. Protein. Expr. Purif 1997, 11: 271-278.
36. Fornwald JA, Donovan MJ, Gerber R, Keller J, Taylor DE Arcuri EJ, Brawner ME, Soluble forms of the human T cell receptor CD4 are efficiently expressed by Streptomyces lividans. Biotechnology(N Y), 1993, 11: 1031-1036.
37. Rajah N, Ysarbopoulos A, Kumarasamy R, O'Donnell R, Taremi SS, Baldwin SW, Sellig GF, Fan XD, Pramanik B, Lee HV, Characterization of recombinant human interleukin 4 receptor from CHO cells: role of N-linked oligosaccharides. Biochemical and Biophysical Research Communication. 1995. 206: 694-702
38．王朝健，中国协和医科大学博士毕业论文，2001，5．
39．姜自彬，中国协和医科大学博士论文，2002，5．
40. Luyten WH, Leysen JE, Receptor cloning and heterologous expression-towoards a new tool for drug discovery. Trends. Biotechnol, 1993, 11: 247-254.
41. Sarubbi E, Yanofsky SD, Barrett RW, Denaro M, A cell-free, nonisotopic, high-throughput assay for inhibitors of type-Ⅰ interleukin-1 receptor. Analytical. Biochemistry, 1996, 237: 70-75.
42. Aretz W, Koller KP, Riess G, Proteolytic enzymes from recombinant Streptomyces lividans TK24. FEMS. Microbiol. Lett, 1989, 65: 31-36.1. Chen HJ, Paul WE, Cultured NK1.1(+)CD4(+) T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J. Immunol. 1997, 159: 2240-2249.
2. Seder RA, Paul WE, Davis MM, Fazekas de St Groth B, The presence of interleukin -4 during in vitro priming determines the lymphokine-producing potential of CD4+ T-cells from T-cell receptor transgenic mice. J. Exp. Med. 1992, 176: 1091-1098.
3. Gascan H, Gauchat JF, Roncarolo MG, Yssel H, Spits H, de Vries JE, Human B cell clones can be induced to proliferate and to swith to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J. Exp. Med 1991, 173: 747-750.
4. Sager N, Feldmann A, Schilling G, Kreitsch P, Neumann C, House dust mite-specific T cells in the skin of subjects with atopic dermatitis: frequency and lymphokine profile in the allergen patch test. J. Allergy. Clin. Immynol. 1992, 89: 801-810.
5. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J.. Med. 1992, 326: 298-304.
6. Daher S, Santos LM, Sole D, De Lima MG, Naspitz CK, Musatti CC, Interleukin-4 and soluble CD23 serum levels in asthmatic atopic children. J. lnvest. Allergol. Clin. Immunol. 1995, 5: 251-254.
7. Leonard C, Tormey V, Burke C, Poulter LW, Allergen-induced cytokine production in atopic disease and its relationship to disease severity. Am. J. Respir. Cell. Mol. Biol. 1997, 17: 368-375.
8. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the Fc epsilonRI, CD40L, IL-4 and IL-13, and can induce IgE synthesis in B cells. J. Clin. lnvest. 1997, 99: 1492-1499.
9. Fanslow WC, Clifford KN, Park LS, Rubin AS, Voice RF, Beckmann MP, Widmer MB. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J. Immunol. 1991, 147: 535-540.
10. Noelle R, Kramme RP, Ohara J, Uhr JW, Vitetta ES, Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. Proc. Natl. Acad. Sci. USA. 1984, 81: 6149-6153.
11. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M, Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcel-2 expression. J. Exp. Med. 1992, 176: 1319-1326.
12. Thomhill MH, Wellicoms SM, Mahiouz DL, Lanchbury JS, Kyan-Aung U, Haskard DO, Tumor necrosis factor combines with IL-4 or IFNgamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J. Immunol. 1991, 146: 592-598.
13. Lowenthal JW, Castle BE, Christiansen J, Schreurs J, Rennick D, Arai N, Hoy P, Takebe??Y, Howard M, Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells. J. Immunol. 1988, 140: 456-464
14. Hage T, Sebald W, Reinemer P, Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface. Cell. 1999, 97: 271-281.
15. Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S, Arai K, Sugamura K, Sharing of the interleukin-2(IL-2) receptor gamma chain between receptors for IL-2 and IL-4[see comment]. Science. 1993, 262: 1874-1877.
16. Watanabe S, Kondo M, Takatsu K, Sugamura K, Arai K, Involvement of the interleukin-2 receptor gamma subunit in interleukin-4-dependent activation of mouse hematopoietic cells and splenic B cells. Eur. J. Immunol. 1995, 25: 126-131.
17. Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Nakamura M, Takeshita T, The common gamma-chain for multiple cytokine receptors. Adv. Immunol. 1995, 59: 225-277.
18. Leonard WJ, The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Annu. Rev. Med. 1996, 47: 229-239
19. Matthews D J, Hibbert L, Friedrich K, Minty A, Callard RE, X-SCID B cell responses to interleukin-4 receptor alpha chain (p140) but not the gamma c chain. Eur. J. Immunol. 1997, 27: 116-121.
20. Hilton DJ, Zhang JG, Metcalf D, Alexander WS, Nicola NA, Willson TA, Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc. Natl. Acad. Sci. USA.1996, 93: 497-501.
21. Miloux B, Laurent P, Bonnin O, Lupker J, Caput D, Vtta N, Ferbrara P, Cloning of the human IL-13R alphal chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex. FEBS. Lett. 1997, 401: 163-166.
22. Lin JX, Migone TS, Tsang M, Friedmann M, Weatherbee JA, Zhou L, Yamauchi A, Bloom ET, Mietz J, John S, The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. lmtnunity. 1995, 2: 331-339.
23. Tony HP, Shen BJ, Reusch P, Sebald W, Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cell and B-cells with high efficiency. Eur. J. Biochem. 1994, 225: 659-665.
24. Shanafelt B, Forte CP, Kasper JJ, Sanchez-Pescador L, Wetzel M, Gundel R, Greve JM, An immune cell-selective interleukin 4 agonist. Proc. Natl. Acad Sci. USA. 1998, 95: 9454-9458.
25. Schnare M, Blum H, Juttner S, Rollinghoff M, Gessner A, Specific antagonism type Ⅰ IL-4 receptor with a mutated form ofmurine IL-4. J. Immunol. 1998, 161: 3484-3492.
26. Pritchard MA, Baker E, Whitmore SA, Sutherland GR, Idzerda RL, Park LS, Cosman D, Jenkins NA, Gilbert D J, Copeland NG. The interleukin-4 receptor gene (IL-4) maps to 16p11.2-16p12.1 in human and to the distal region of mouse chromosome 7. Genetics. 1991, 10: 801-806.
27. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA. Functional mimicry of a protein hormone by a peptide agonist:??the EPO receptor complex at 2.8 A. Science. 1996, 273: 464-471.
28. Reusch A, Arnold S, Heusser C, Wagner K, Weston B, Schald W, Neutralizing monoclonal antibodies define two different functional sites of human interleukin-4. J. Biochem. 1994, 222: 491-499.
29. Mitsuyasu H, Izuhara K, Mao XQ, Gao PS, Arinobu Y, Enomoto T, Kawai M, Sasaki S, Dake Y, Hamasaki N, Shirakawa T, Hopkin JM. Ile50Val variant of IL-4Ralpha upregulates IgE synthesis and associates with atopic asthma. Nature Genetics, 1998, 19: 119-120.
30. Bazaan, JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA. 1990, 87: 6934-6938.
31. Ihle JN, The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv. Immunol. 1995, 60:1-35.
32. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA, Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science. 1991, 254:821-250.
33. Kammer W, Lischke A, Moriggl R, Groner B, Ziemiecki A, Gurniak CB, Berg LJ, Friedrich K, Homodimerization of interleukin-4 receptor alpha chain can induce intracellular signaling. J. Biol. Chem. 1996, 271: 23634-23637.
34. Taniguchi T, Cytokine signaling through nonreceptor protein tyrosine kinases. Science. 1995, 268: 251-255.
35. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET, Ihle JN, Involvement of the Jak-3 Janus kinase in signaling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature. 1994, 370: 153-157.
36. Miyazaki T, Kawahara A, Fujii H, Nakagawa Y, Minami Y, Liu ZJ, Oishi I, Silvennoinen O, Witthahn BA, Ihle JN, et al, Functional activation of Jak 1 and Jak3 by selective association with IL-2 receptor subunits. Science. 1994, 266: 1045-1047.
37. Deutsch HH, Koettnitz K, Chung J, Kalthoff FS, Distinct sequence motifs within the cytoplasmic domain of the human IL-4 receptor differentially regulate apoptosis inhibition and cell growth. J. Immunol. 1995, 154:3696-3703.
38. Izuhara K, Feldman RA, Greer P, Harada N, Interaction of the c-fes protooncogene product with the interleukin-4 receptor. J. Biol. Chem. 1994, 269: 18623-18629.
39. Ryan JJ, McReynolds LJ, Keegan A, Wang LH, Garfein E, Rothman P, Nelms K, Paul WE, Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor. Immunity. 1996, 4: 123-132.
40. Wang HY, Paul WE, Keegan AD, IL-4 function can be transferred to the IL-2 receptor by tyrosine containing sequences found in the IL-4 receptor alpha chain. Immunity. 1996, 4:113-121.
41. Gustafson TA, He W, Craparo A, Schaub CD, O'Neill TJ, Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Mol. Cell. Biol. 1995, 15:2500-2508.
42. Trub T, Choi WE, Wolf G, Ottinger E, Chen Y, Weiss M, Shoelson SE, Specificity of thePTB domain of She for beta turn-forming pentapeptide motifs amino- terminal to phosphotyrosine. J. Biol Chem. 1995, 270: 18205-18208.
43. Wolf G, Trub T, Ottinger E, Groninga L, Lynch A, White M, Miyazaki M, Lee J, Shoelson SE, The PTB domains of IRS-1 and She have distinct but overlapping binding specificities. J. Biol. Chem. 1995, 270: 27407-27410.
44. Eck MJ, Dhe-Paganon S, Trub T, Nolte RT, Shoelson SE, Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. Cell. 1996, 85: 695-705.
45. Wang HY, Zamorano J, Keegan AD, A role for the insulin-interleukin-4 receptor motif of the IL-4 receptor alpha-chain in regulating activation of the insulin receptor substrate-2 and signal transducer and activator or transcription 6 pathways. Analysis by mutagenesis. J. Biol. Chem. 1998, 273: 989-9905.
46. Lemmon MA, Ferguson KM, Sigler PB, Schlessinger J, Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain. Proc. Natl. Acad. Sci. USA. 1995, 92: 10472-10476.
47. Yin TG, Keller SR, Quelle FW, Witthuhn BA, Tsang MLS, Lienhard GE, Ihle JN, Yang YC, Interleukin-9 induces tyrosine phosphorylation of insulin-receptor substrate-1 via Jak tyrosine kinases. J. Biol. Chem 1995, 270: 20497-20502.
48. Johnston JA, Wang LM, Hanson EP, Sun XJ, White MF, Oakes SA, Pierce JH, O'Shea JJ, Interleukins 2, 4, 7, and 15 stimulate tyrosine phosphorylation of insulin receptor substrates 1 and 2 in T cells. Potential role of JAK kinases. J. Biol. Chem. 1995, 270: 28527-28530.
49. Wang HY, Zamorano J, Yoerkie JL, Paul WE, Keegan AD, The EL-4-induced tyrosine phosphorylation of the insulin receptor substrate is dependent on JAK1 expression in human fibrosarcoma cells. J. Immuno. 1997, 158: 1037-1040.
50. Sun XJ, Crimmins DL, Myers MG, Miralpeix M, White MF, Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol. Cell. Biol. 1993, 13: 7418-7428,
51. Dhand R, Hiles I, Panayotou G, Roche S, Fry MJ, Gout I, Totty NF, Truong O, Vicendo P, Yonezawa K, et al, PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J. 1994, 13:522-533.
52. Stephens LR, Jackson TR, Hawkins PT, Agonist-stimulated synthesis of phosphatidylinosito(3,4,5)-trisphosphate: a new intracellular signaling system? Biochim. Biophys. Acta. 1993, 1179: 27-75.
53. Franke TF, Kaplan DR, Cantley LC, Toker A, Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 1997, 275: 665-668.
54. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y, A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J. Bio. Chem. 1997, 272: 29911-29918.
55. Druronio V, Welham MJ, Abraham S, Dryden P, Schrader JW, p21ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating protein. Proc. Natl. Acad. Sci. USA. 1992, 89: 1587-1591.
56 Chardin P, Camonis JH, Gale NW, van Aelst L, Schlessinger J, Wigler MH, BarSagi D, Human Sos 1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science. 1993, 260: 1338-1343.
57. Denhardt DT, Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signaling. Bochem. J. 1996, 318:729-747.
58. Welham MJ, Learmonth L, Bone H, Schrader JW, Interleukin-13 signal transduction in lymphohemooietic cells. Similarities and differences in signal transduction with interleulin-4 and insulin. J. Biol. Chem. 1995, 270: 12286-12296.
59. Wery S, Letourneur M, Bertoglio J, Pierre J, Interleulin-4 induces activation of mitogen-activated protein kinase and phosphorylation of she in human keratinocytes. J. Biol. Chem. 1996 271: 8529-8532
60. Rozakis-Adcock M, McGlade J, Mbamalu G Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, et al, Association of the She and Grb2/Sem5 SH2-containning protein is implicated in activation of the Ras pathway by tyrosine kinases. Nature. 1992, 360: 689-692.
61. Ueno H, Sasaki K, Honda H, Nakamoto T, Yamagata T, Miyagawa K, Mitani K, Yazaki Y, Hirai H, c-Cb1 is tyrosinephosphorylated by interleukin-4 and enhances mitogenic and survival signals of interleukin-4 receptor by linking with the phosphatidylinostitol 3'-kinase pathway. Blood 1998, 91: 46-53.
62. Velazquez L, Fellous M, Stark GR, Pellegrini S, A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992 70: 313-322
63. Nakanishi K, Yoshida N, Kishimoto T, Akira S, Essential role of Stat-6 in IL-4 signalling. Nature. 1996, 380:627-630.
64. Mikita T, Campbell D, Wu PG Williamson K, Schindler U, Requirements for interleulin-4-induced gene expression and functional characterization of Stat-6. Mol. Cell. Biol. 1996, 16: 5811-20.
65. Schindler U, Wu P, Rothe M, Brasseur M, McKnight SL, Components of a Stat recognition code: evidence for two layers of molecular selectivity. Immunity. 1995, 2: 689-697.
66. Richter G, Hein G, Blakenstein T, Diamantstein T, The rat interleukin 4 receptor: coevolution of ligand and receptor. Cytokine. 1995, 7:237-241.
67. Ryan JJ, McReynolds LJ, Huang H, Nelms K, Paul WE, Characterization of a mobile Stat-6 motif in the human IL-4 receptor. J. Immunol. 1998, 161: 1811-1821.
68. Kim J, Reeves R, Rothman P, Boothby M, The non-histone chromosomal protein HMG-1(Y) contributes to repression of the immunoglobulin heavy chain germ-line epsilon RNA promoter. Eur. J. Immunol. 1995, 25: 789-808.
69. Muller M, Laxton C, Briscoe J, Schindler C, Improta T, Darnell JE Jr, Stark GR, Kerr IM, Complementation of a mutant cell line: central role of the 91kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways. EMBO J. 1993, 12:4221-4228.
70. Patel BKR, Pierce JH, LaRochelle WJ, Regulation of interleukin 4-mediated signaling by naturally occurring dominant negative and attenuated forms of human Stat-6. Proc. Natl. Acad. Sci. USA. 1998, 95: 172-177.
71. Delphin S, Stavnezer J, Characterization of an interleukin 4 (IL4) responsive region in the immunoglobulin heavy chain germline epsilon promoter: regulation by NG-IL-4 a C/EBP family member and NF-kappa B/p50. J. Exp. Med. 1995, 181: 181-192.
72. Wen Z, Zhong Z, Darnell JE Jr, Maximal activation of transcription by Stat 1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995, 82: 241-250.
73. Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S, Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science. 1995, 267: 1990-1994.
74. Urban JF Jr, Noben-Trauth N, Donaldson DD, Madden KB, Morris SC, Collins M, Finkelman FD, IL-13, IL-4Ralpha, and Stat-6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity. 1998, 8: 255-264.
75. Kaplan MH, Daniel C, Schindler U, Grusby MJ, Stat proteins control lymphocyte proliferation by regulating p27(Kip 1) expression. Mol. Cell. Biol. 1998, 18: 1996-2003.
76. Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA, The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N. Engl. J. Med. 1997, 337: 1720-1725.
77. Hou JZ, Schindler U, Henzel WJ, Ho TC, Brasseur M, McKnight SL, An interleukin-4-induced transcription factor-IL-4 Stat. Science. 1994, 265: 1701-1706.
78. D'Ambrosio D, Hippen KL, Minskoff SA, Mellman I, Pani G, Siminovitch KA, Cambier JC, Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1. Science. 1995, 268: 293-297.
79. Sun XJ, Pons S, Wang LM, Zhang Y, Yenush L, Burks D, Myers MG Jr, Glasheen E, Copeland NG, Jenkins NA, Pierce JH, White MF, The IRS-2-gene on murine chromosome 8 encodes a unique signaling adapter for insulin and cytokine action. Mol. Endocrinol. 1997, 11:251-262.
80. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE, Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998, 92: 441-450.
81. David M, Chen HE, Goelz S, Larner AC, Neel BG, Differential regulation of the alpha/beta interferonstimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 1995, 15: 7050-7058.
82. Damen JE, Liiu L, Rosten P, Humphries RK, Jefferson AB, Majerus PW, Krystal G, The 145kDa protein induced to associate with She by multiple cytokines is an inostiol tetraphosphate and phosphatidylinositol 3,4,50triphosphate 5-phosphatase. Proc. Natl.Acad. Sci, USA 1996, 93: 1689-1693.
83. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A, A new protein containing an SH2 domain that inhibits JAK kinase. Nature. 1997, 387: 921-924.
84. Boguski MS, McCormick F, Proteins regulating Ras and its relatives. Nature. 1993, 366 643-654.
85. Yamanashi Y, Baltimore D, Identification of the Abl- and rasGAP-associated 62kDa protein as a docking protein, Dok. Cell. 1997, 88: 205-211.
86. Meier H, Myers DD, Huebner RJ, Genetic control by the hr-locus of susceptibility and resistance to leukemia. Proc. Natl. Acad. Sci. 1963, 63: 759-766.
87. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM, Maintenance of human T cell anergy: blocking of Ⅱ-2 gene transcription by activated Rapl. Science. 1997, 278: 124-128.
88. Noben-Trauth N, Shultz L. D, Brombacher F, Urban J. F, Gu H, Paul WE, An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc. Natl. Acad. Sci. USA. 1997, 94: 10838-10843.
89. Schulte T, Kurrle R, Rollinghoff M, Gessner A, Molecular characterization and functional analysis of murine interleukin 4 receptor allotypes. J. Exp. Med. 1997, 186: 1419-1429.
90. Hackstin H, Kluter H, Fricke L, Hoyer J, Bein G, The IL-4 receptor alpha-chain variant Q576R is strongly associated with decreased kidney allograft survival. Tissue. Antigens. 1999, 54: 471-477.
91. Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokuchi K, Imoto N, Nakahara S, Matsui A, Hamaguchi H, Lack of association of atopy/asthma and the interleukin-4 reeptor alpha gene in Japanese. Clin. Exp. Allergy. 1999, 29: 228-233.
92. Dastot F, Sobrier ML, Duquesnoy P, Duriez B, Goossens M, Amselem S, Alternatively spliced forms in the cytoplasmic domain of the human growth hormone (GH) receptor regulate its ability to generate a soluble GH-binding protein. Proc. Natl. Acad. Sci. USA. 1996, 93: 10723-10728.
93. Skoda RC, Seldin DS, Chiang MK, Peichel CL, Leder P, Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBOJ. 1993, 12: 2645-2653.
94. Kruse S, Forster J, Kuehr J, Deichmann KA. Characterization of the membrane-bound and a soluble form of human IL-4 receptor α produced by alternative splicing. International,. Immunology. 1999, 11: 1965-1969.
95. Jung T, Schrader N, Hellwig M, Enssle KH, Neumann C. Soulble human interleukin-4 receptor is produced by activated T cells under the control of metalloproteinases, Int. Arch. Allergy. Immunol. 1999, 119: 23-30.
96. Baumann G., Shaw MA, Buchanan TA, In vivo kinetics of a covalent growth hormone-binding protein complex. Metabolism. 1989, 38: 330-333.
97. Ku H, Hirayama F, Kato T, Miyazaki H, Aritomi M, Ota Y, D'Andrea AD, Lyman SD,??Ogawa M, Soluble thrombopoietin receptor and granulocyte colony-stimulating factor receptor directly stimulate proliferation of primitive hematopoietic progenitors of mice in synergy with steel factor or the ligand of Flt3/Flk2. Blood 1996, 88: 4124-4131.
98. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D, Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 1992, 175: 323-329.
99. Rose-John S, Ehlers M, Grotzinger J, Mullberg J, The soluble interleukin-6 receptor. Ann. NY Acad. Sci. 1995, 762: 207-220.
100. Fernandez-Botran R, Chilton PM, Ma Y, Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy. Adv. Immunol. 1996, 63: 269-336.
101. Heaney ML, Golde DW, Soluble receptors in human disease. J. Leukoc. Biol. 1998, 64: 135-146.
102. Fernanadez-Botran R, Vitetta ES, A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. Proc. Natl. Acad. Sci. USA. 1990, 87: 4202-4206.
103. Sang DK, Ouma JH, John CC, Whalen CC, King CL, Mahmoud AA, Heinzel FP, Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. J. Infect. Dis. 1999, 179: 743-746.
104. Chilton PM, Fernandez-Botran R, Regulation of the expression of the soluble and membrane forms of the murine IL-4 receptor. Cell. Immunol. 1997, 180: 104-115.
105. Garrone P, Djossou O, Galizzi JP, Banchereau J, A recombinant extracellular domain of the human interleukin 4 receptor inhibits the biological effects of interleukin 4 on T and Blymphocytes. Eur. J. Immunol. 1991, 21: 1365-1369.
106. Maliszewski CR, Sato TA, Vanden Bos T, Waugh S, Dower SK, Slack J, Beckmann MP, Grabstein KH, Cytokine receptors and B cell functions. I. recombi.nant soluble receptors specifically inhibit IL-1- and IL-4-induced B cell activities in vitro. J. Immuno. 1990, 144: 3028-3033.
107. Fernandez-Botran R, Vitetta ES, Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J. Exp. Med. 1991, 174: 673-681.
108. Gessner A, Schroppel L, Will A, Enssle KH Lauffer L, Rollinghoff M, Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous Leishmaniasis. Infec. Immun. 1994, 62: 4112-4117.
109. Puccetti P, Mencacci A, Cenci E, Spaccapelo R, Mosci P, Enssle KH, Romani L, Bistiohi F, Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J. Inect. Dis. 1994, 169: 1325-1331.
110. Renz H, Enssle K, Lauffer L, Kurrle R, Gelfand E. W, Inhibition of allergen-induced IgE and IgG1 production by soluble IL-4 receptor. Int. Arch. Allergy. Immunol. 1995, 106: 46-54.
111. Renz H, Bradley K, Enssle K, Loader JE, Larsenx EW, Gelfand EW, Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor. Int. Arch. Allergy. Immuno. 1996, 109: 167-176.112. Kobayashi H, Kobayashi M, Utsunomiya T, Hemdon DN, Pollard RB, Susuki F, Therapeutic protective effects of IL-12 combined with soluble IL-4 receptor against established infections of herpes simplex virus type 1 in thermally injured mice. J. Immunol. 1999, 162: 7148-7154.
113. Kay AB. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 2001, 344: 30-37.
114. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J. Clin. Invest. 1999, 104: 1001-1006.
115. Vogel G. New clues to asthma therapies. Science. 1997, 276: 1643-1646.
116. Barnes PJ. Cytokine-directed therapies for asthma. J. Allergy. Clin. Immunol. 2001, 108: S72-S76.
117. Sano Y, Suzuki N, Yamada H, To Y, Ogawa C, Ohta K, Adachi M. Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma. J. Allergy. Clin. Immunol. 2003, 111: 958-966.
118. Harbinson PL, MacLeod D, Hawksworth R, O' Toole S, Sullivan PJ, Heath P, Kilfeather S, Page CP, Costello J, Holgate ST, Lee TH. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur: Respir. J. 1997, 10: 1008-1014.
119. O' Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J. Allergy. Clin. Immunol. 2001, 108: 503-508.
120. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil' s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care. Med. 2003, 167: 199-204.
121. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore J-B, Agosti JM. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy. Clin. Immunol. 2001, 107: 963-970.
122. Barnes PJ. Current Therapy for Asthma. Hansel TT, Barnes PJ(eds): New Drugs for Asthma, Allergy and COPD. Prog. Respir. Resr: 2001, 31: 6-10.
123. Borish L, Agosti JM. Interleukin-4 Antagonism. Hansel TT, Barnes PJ(eds): New Drugs for Asthma, Allergy and COPD. Prog. Respir. Res. 2001, 31: 256-259.
124. Vella A, Teague TK, Ihle J, Kappler J, Marrack P. Interleukin 4(IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-4. J. Exp. Med. 1997, 186: 325-330.
125. Evans TJ, Moyes D, Carpenter A, Martin R, Cohen J, Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptore-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J. Exp. Med. 1994, 180: 2173-2179.
126. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garriso L. Interleukin-4 receptor in moderate atopic asthma: A phase Ⅰ/Ⅱ randomized, placebo-controlled trial. Am. J. Respir. Crit. Care. Med. 1999, 160: 1816-1823.
127. Pollock HW, Ebert CS, Dubin MG, White DR, Prazma J, Pillsbury HC 3rd. The role of soluble interleukin-4 receptor and interleukin-5 ntibody in preventing late-phase??allergy-induced eustachian tube dysfunction. Otolaryngol. Head. Neck. Surg. 2002, 127: 169-176.
128. Katakura T, Kobayashi M, Fujita K, Herndon DN, Pollard RB, Suzuki F, A Combination Therapy Using IL-12 and Soluble IL-4 Receptor on Herpes Simplex Virus Type 1 Infection in a Human-SCID Chimera Model of Thermal Injury. Clin. Immunol. 2002, 105: 363-370.
129. Kobayashi M, Takahashi H, Herndon DN, Pollard RB, Suzuki F. Effect of a combination therapy between IL-12 and soluble IL-4 receptor (slL-4R) on Candida albicans and herpes simplex vierus type 1 infections in thermally injured mice. Can. J. Microbiol. 2002, 48: 886-894.
2. Seder RA, Paul WE, Davis MM, Fazekas de St Groth B, The presence of interleukin-4 during in vitro priming determines the lymphokine-producing potential of CD4+ T-cells from T-cell receptor transgenic mice. J. Exp. Med. 1992, 176: 1091-1098.
3. Gascan H, Gauchat JF, Roncarolo MG, Yssel H, Spits H, de Vries JE, Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J. Exp. Med. 1991, 173: 747-750.
4. Sager N, Feldmann A, Schilling G, Kreitsch P, Neumann C, House dust mite-specific T cells in the skin of subjects with atopic dermatitis: frequency and lymphokine profile in the allergen patch test. J. Allergy. Clin. Immynol. 1992, 89: 801-810.
5. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C, Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the Fc epsilonRI, CD40L, IL-4 and IL-13, and can induce IgE synthesis in B cells. J. Clin. Invest. 1997, 99: 1492-1499.
6. Duschl A, Sebald W, Transmembrane and intracellular signalling by interleukin-4: receptor dimerization and beyond. Eur Cytokine. Netw. 1996, 7(1): 37-49.
7. Pritchard MA, Baker E, Whitmore SA, Sutherland GR, Idzerda RL, Park LS, Cosman D, Jenkins NA, Gilbert DJ, Copeland NG, et al, The interleukin-4 receptor gene (IL-4) maps to 16p 11.2-16p 12.1 in human and to the distal region of mouse chromosome 7. Genetics. 1991, 10: 801-806.
8. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA, Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science. 1996, 273: 464-471.
9. Mitsuyasu H, Izuhara K, Mao XQ, Gao PS, Arinobu Y, Enomoto T, Kawai M, Sasaki S, Dake Y, Hamasaki N, Shirakawa T, Hopkin JM, Ile50Val variant of IL-4Ralpha upregulates IgE synthesis and associates with atopic asthma. Nature. Genetics. 1998, 19: 119-120.
10. Barnes PJ, Current Therapy for Asthma. Hansel TT, Barnes PJ (Eds): New Drugs for Asthma, Allergy and COPD. Prog. Respir Resr. 2001, 31: 6-10.
11. Vella A, Teague TK, Ihle J, Kappler J, Marrack P, Interleukin 4(IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-4. J. Exp. Med. 1997, 186: 325-330.
12. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garriso L. Interleukin-4 receptor in moderate atopic asthma: A phase Ⅰ/Ⅱ randomized, placebo-controlled trial. Am. J. Respir. Crit. Care. Med. 1999, 160: 1816-1823.
13. Pollock HW, Ebert CS, Dubin MG, White DR, Prazma J, Pillsbury HC 3rd, The role of??soluble interleukin-4 receptor and interleukin-5 ntibody in preventing late-phase allergy-induced eustachian tube dysfunction. Otolaryngol. Head Neck. Surg. 2002, 127: 169-176.
14. Katakura T, Kobayashi M, Fujita K, Herndon DN, Pollard RB, Suzuki F, A Combination Therapy Using IL-12 and Soluble IL-4 Receptor on Herpes Simplex Virus Type 1 Infection in a Human-SCID Chimera Model of Thermal Injury. Clin. Immunol. 2002, 105: 363-370.
15. Jung T, Wagner K, Neumann C, Heusser CH. Enhancement of human IL-4 activity by soluble IL-4 receptors in vitro. Eur. J. Immunol. 1999, 29: 864-871.
16. Idzerda RL, March CJ, Mosley B, Lyman SD, Bos TV, Gimple SD, Din WS, Grabstein KH, Widmer MB, Park LS, Cosman D, Beckmann MP, Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J. Exp. Med 1990, 171: 861-873.
17. Sambrook J, Fritsch EF, Maniatis T, Molecular cloning, A Laboratory Manual, 2nd ed, Cold Spring Harbor Laboratory Press, 1989.
18．霍普伍德等著，邓子新，唐纪良译链霉菌操作手册，湖南科学技术出版社．
19. Zhang Zhiqing, Yao Lihong, Hou Yunde, Construction and application of a high level expression vector containing P_RP_L promoter. Chinese. Journal of Virology. 1990, 6: 111-116.
20. Cregg JM, Cereghino JL, Shi J, Higgins DR, Recombinant protein expression in Pichia pastoris. Molecular Biotechinology. 2000, 16: 23-52.
21. Bochkov VN, Tkachuk VA, Philippova MP, Stambolsky DV, Buhler FR, Resink TJ, Ligand selectivity of 105kD and 130kD lipoprotein-binding proteins in vascular-smooth-muscle-cell membranes is unique. Biochem. J. 1996, 317: 297-304.
22. Bradford MM, McRorie RA, Williams WL, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254.
23. Klaus D, Jurgen B, Johannes F, Andrea H, Joachim K, Common Polymorphisms in the Coding Part of the IL4-Receptor gene. Biochemical And Biophysical Research Communications. 1997, 231: 696-697.
24. Hitzeman RA, Hagie FE, Levine HL, Goeddel DV, Ammerer G, Hall BD, Expreession of a human gene for interferon inyeast. Nature. 1981, 293: 717-722.
25. Clare JJ, Rayment FB, Ballantine SP, Sreekrishna K, Romanos MA, High-level expression of tetanus toxin frangment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Bio/Technology. 1991, 9: 455-460.
26. Rosenfeld SA, Nadeau D, Tirado J, Hollis GF, Knabb RM, Jia S, Production and purification of recombinant hirudin expresses in the methylotrophic yeast Pichia pastoris. Protein. Expr. Purer. 1996, 8: 476-482.
27. Kukuruzinska MA, Bergh MLE, Jackson BJ, Protein glycosylation in yeast. Ann. Rev. Biochem. 1987, 56: 915-955.
28. Romanos MA, Scorer CA, Clare JJ, Foreign gene expression in yeast: a review. Yeast.??1992．8：423-488．
29．张华，中国协和医科大学博士毕业论文，1999，6．
30. Mezes PSE Lampen JO, Secretion of proteins by bacilli. In Dubnau D (Ed.), The Molecular Biology of the Bacilli. Acadamic Press, New York, 1985, 151-183.
31. Monlnar I, Murooka Y, Imanaka T, Recombinant Microbes for Industrial and Agricultural Applications. New York: Maecel Dekker Inc, 1994, 81-104.
32. Gilbert M, Morosoli R, Shareck F, Kluepfel D, Production and secretion of proteins by streptomycetes. Crit. Rev. Biotechnol. 1995, 15(1): 13-39.
33. Binnie C, Cossar J D, Stewart D I, Heterologous biopharmaceutical protein expression in streptornyces. Trends. Biotech. 1997, 15: 315-320.
34. Shen BJ, Hage T, Sebald W, Global and local determinants for the kinetics of interleukin-4/interleukin-4 receptor α chain interaction: A biosensor study employing recombinant interleukin-4-binding protein. Eur. J. Biochem. 1996, 240: 251-261.
35. Binnie C, Jenish D, Cossar D, Szabo A, Trudeau D, Krygsman E Malek LT, Stewart DI, Expression and characterization of soluble human erythropoietin receptor made in Streptomyces lividans 66. Protein. Expr. Purif 1997, 11: 271-278.
36. Fornwald JA, Donovan MJ, Gerber R, Keller J, Taylor DE Arcuri EJ, Brawner ME, Soluble forms of the human T cell receptor CD4 are efficiently expressed by Streptomyces lividans. Biotechnology(N Y), 1993, 11: 1031-1036.
37. Rajah N, Ysarbopoulos A, Kumarasamy R, O'Donnell R, Taremi SS, Baldwin SW, Sellig GF, Fan XD, Pramanik B, Lee HV, Characterization of recombinant human interleukin 4 receptor from CHO cells: role of N-linked oligosaccharides. Biochemical and Biophysical Research Communication. 1995. 206: 694-702
38．王朝健，中国协和医科大学博士毕业论文，2001，5．
39．姜自彬，中国协和医科大学博士论文，2002，5．
40. Luyten WH, Leysen JE, Receptor cloning and heterologous expression-towoards a new tool for drug discovery. Trends. Biotechnol, 1993, 11: 247-254.
41. Sarubbi E, Yanofsky SD, Barrett RW, Denaro M, A cell-free, nonisotopic, high-throughput assay for inhibitors of type-Ⅰ interleukin-1 receptor. Analytical. Biochemistry, 1996, 237: 70-75.
42. Aretz W, Koller KP, Riess G, Proteolytic enzymes from recombinant Streptomyces lividans TK24. FEMS. Microbiol. Lett, 1989, 65: 31-36.1. Chen HJ, Paul WE, Cultured NK1.1(+)CD4(+) T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J. Immunol. 1997, 159: 2240-2249.
2. Seder RA, Paul WE, Davis MM, Fazekas de St Groth B, The presence of interleukin -4 during in vitro priming determines the lymphokine-producing potential of CD4+ T-cells from T-cell receptor transgenic mice. J. Exp. Med. 1992, 176: 1091-1098.
3. Gascan H, Gauchat JF, Roncarolo MG, Yssel H, Spits H, de Vries JE, Human B cell clones can be induced to proliferate and to swith to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J. Exp. Med 1991, 173: 747-750.
4. Sager N, Feldmann A, Schilling G, Kreitsch P, Neumann C, House dust mite-specific T cells in the skin of subjects with atopic dermatitis: frequency and lymphokine profile in the allergen patch test. J. Allergy. Clin. Immynol. 1992, 89: 801-810.
5. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J.. Med. 1992, 326: 298-304.
6. Daher S, Santos LM, Sole D, De Lima MG, Naspitz CK, Musatti CC, Interleukin-4 and soluble CD23 serum levels in asthmatic atopic children. J. lnvest. Allergol. Clin. Immunol. 1995, 5: 251-254.
7. Leonard C, Tormey V, Burke C, Poulter LW, Allergen-induced cytokine production in atopic disease and its relationship to disease severity. Am. J. Respir. Cell. Mol. Biol. 1997, 17: 368-375.
8. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitis exhibit increased expression of the Fc epsilonRI, CD40L, IL-4 and IL-13, and can induce IgE synthesis in B cells. J. Clin. lnvest. 1997, 99: 1492-1499.
9. Fanslow WC, Clifford KN, Park LS, Rubin AS, Voice RF, Beckmann MP, Widmer MB. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J. Immunol. 1991, 147: 535-540.
10. Noelle R, Kramme RP, Ohara J, Uhr JW, Vitetta ES, Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. Proc. Natl. Acad. Sci. USA. 1984, 81: 6149-6153.
11. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M, Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcel-2 expression. J. Exp. Med. 1992, 176: 1319-1326.
12. Thomhill MH, Wellicoms SM, Mahiouz DL, Lanchbury JS, Kyan-Aung U, Haskard DO, Tumor necrosis factor combines with IL-4 or IFNgamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J. Immunol. 1991, 146: 592-598.
13. Lowenthal JW, Castle BE, Christiansen J, Schreurs J, Rennick D, Arai N, Hoy P, Takebe??Y, Howard M, Expression of high affinity receptors for murine interleukin 4 (BSF-1) on hemopoietic and nonhemopoietic cells. J. Immunol. 1988, 140: 456-464
14. Hage T, Sebald W, Reinemer P, Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface. Cell. 1999, 97: 271-281.
15. Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S, Arai K, Sugamura K, Sharing of the interleukin-2(IL-2) receptor gamma chain between receptors for IL-2 and IL-4[see comment]. Science. 1993, 262: 1874-1877.
16. Watanabe S, Kondo M, Takatsu K, Sugamura K, Arai K, Involvement of the interleukin-2 receptor gamma subunit in interleukin-4-dependent activation of mouse hematopoietic cells and splenic B cells. Eur. J. Immunol. 1995, 25: 126-131.
17. Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Nakamura M, Takeshita T, The common gamma-chain for multiple cytokine receptors. Adv. Immunol. 1995, 59: 225-277.
18. Leonard WJ, The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Annu. Rev. Med. 1996, 47: 229-239
19. Matthews D J, Hibbert L, Friedrich K, Minty A, Callard RE, X-SCID B cell responses to interleukin-4 receptor alpha chain (p140) but not the gamma c chain. Eur. J. Immunol. 1997, 27: 116-121.
20. Hilton DJ, Zhang JG, Metcalf D, Alexander WS, Nicola NA, Willson TA, Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc. Natl. Acad. Sci. USA.1996, 93: 497-501.
21. Miloux B, Laurent P, Bonnin O, Lupker J, Caput D, Vtta N, Ferbrara P, Cloning of the human IL-13R alphal chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex. FEBS. Lett. 1997, 401: 163-166.
22. Lin JX, Migone TS, Tsang M, Friedmann M, Weatherbee JA, Zhou L, Yamauchi A, Bloom ET, Mietz J, John S, The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. lmtnunity. 1995, 2: 331-339.
23. Tony HP, Shen BJ, Reusch P, Sebald W, Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cell and B-cells with high efficiency. Eur. J. Biochem. 1994, 225: 659-665.
24. Shanafelt B, Forte CP, Kasper JJ, Sanchez-Pescador L, Wetzel M, Gundel R, Greve JM, An immune cell-selective interleukin 4 agonist. Proc. Natl. Acad Sci. USA. 1998, 95: 9454-9458.
25. Schnare M, Blum H, Juttner S, Rollinghoff M, Gessner A, Specific antagonism type Ⅰ IL-4 receptor with a mutated form ofmurine IL-4. J. Immunol. 1998, 161: 3484-3492.
26. Pritchard MA, Baker E, Whitmore SA, Sutherland GR, Idzerda RL, Park LS, Cosman D, Jenkins NA, Gilbert D J, Copeland NG. The interleukin-4 receptor gene (IL-4) maps to 16p11.2-16p12.1 in human and to the distal region of mouse chromosome 7. Genetics. 1991, 10: 801-806.
27. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA. Functional mimicry of a protein hormone by a peptide agonist:??the EPO receptor complex at 2.8 A. Science. 1996, 273: 464-471.
28. Reusch A, Arnold S, Heusser C, Wagner K, Weston B, Schald W, Neutralizing monoclonal antibodies define two different functional sites of human interleukin-4. J. Biochem. 1994, 222: 491-499.
29. Mitsuyasu H, Izuhara K, Mao XQ, Gao PS, Arinobu Y, Enomoto T, Kawai M, Sasaki S, Dake Y, Hamasaki N, Shirakawa T, Hopkin JM. Ile50Val variant of IL-4Ralpha upregulates IgE synthesis and associates with atopic asthma. Nature Genetics, 1998, 19: 119-120.
30. Bazaan, JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA. 1990, 87: 6934-6938.
31. Ihle JN, The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv. Immunol. 1995, 60:1-35.
32. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA, Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science. 1991, 254:821-250.
33. Kammer W, Lischke A, Moriggl R, Groner B, Ziemiecki A, Gurniak CB, Berg LJ, Friedrich K, Homodimerization of interleukin-4 receptor alpha chain can induce intracellular signaling. J. Biol. Chem. 1996, 271: 23634-23637.
34. Taniguchi T, Cytokine signaling through nonreceptor protein tyrosine kinases. Science. 1995, 268: 251-255.
35. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET, Ihle JN, Involvement of the Jak-3 Janus kinase in signaling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature. 1994, 370: 153-157.
36. Miyazaki T, Kawahara A, Fujii H, Nakagawa Y, Minami Y, Liu ZJ, Oishi I, Silvennoinen O, Witthahn BA, Ihle JN, et al, Functional activation of Jak 1 and Jak3 by selective association with IL-2 receptor subunits. Science. 1994, 266: 1045-1047.
37. Deutsch HH, Koettnitz K, Chung J, Kalthoff FS, Distinct sequence motifs within the cytoplasmic domain of the human IL-4 receptor differentially regulate apoptosis inhibition and cell growth. J. Immunol. 1995, 154:3696-3703.
38. Izuhara K, Feldman RA, Greer P, Harada N, Interaction of the c-fes protooncogene product with the interleukin-4 receptor. J. Biol. Chem. 1994, 269: 18623-18629.
39. Ryan JJ, McReynolds LJ, Keegan A, Wang LH, Garfein E, Rothman P, Nelms K, Paul WE, Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor. Immunity. 1996, 4: 123-132.
40. Wang HY, Paul WE, Keegan AD, IL-4 function can be transferred to the IL-2 receptor by tyrosine containing sequences found in the IL-4 receptor alpha chain. Immunity. 1996, 4:113-121.
41. Gustafson TA, He W, Craparo A, Schaub CD, O'Neill TJ, Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Mol. Cell. Biol. 1995, 15:2500-2508.
42. Trub T, Choi WE, Wolf G, Ottinger E, Chen Y, Weiss M, Shoelson SE, Specificity of thePTB domain of She for beta turn-forming pentapeptide motifs amino- terminal to phosphotyrosine. J. Biol Chem. 1995, 270: 18205-18208.
43. Wolf G, Trub T, Ottinger E, Groninga L, Lynch A, White M, Miyazaki M, Lee J, Shoelson SE, The PTB domains of IRS-1 and She have distinct but overlapping binding specificities. J. Biol. Chem. 1995, 270: 27407-27410.
44. Eck MJ, Dhe-Paganon S, Trub T, Nolte RT, Shoelson SE, Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. Cell. 1996, 85: 695-705.
45. Wang HY, Zamorano J, Keegan AD, A role for the insulin-interleukin-4 receptor motif of the IL-4 receptor alpha-chain in regulating activation of the insulin receptor substrate-2 and signal transducer and activator or transcription 6 pathways. Analysis by mutagenesis. J. Biol. Chem. 1998, 273: 989-9905.
46. Lemmon MA, Ferguson KM, Sigler PB, Schlessinger J, Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain. Proc. Natl. Acad. Sci. USA. 1995, 92: 10472-10476.
47. Yin TG, Keller SR, Quelle FW, Witthuhn BA, Tsang MLS, Lienhard GE, Ihle JN, Yang YC, Interleukin-9 induces tyrosine phosphorylation of insulin-receptor substrate-1 via Jak tyrosine kinases. J. Biol. Chem 1995, 270: 20497-20502.
48. Johnston JA, Wang LM, Hanson EP, Sun XJ, White MF, Oakes SA, Pierce JH, O'Shea JJ, Interleukins 2, 4, 7, and 15 stimulate tyrosine phosphorylation of insulin receptor substrates 1 and 2 in T cells. Potential role of JAK kinases. J. Biol. Chem. 1995, 270: 28527-28530.
49. Wang HY, Zamorano J, Yoerkie JL, Paul WE, Keegan AD, The EL-4-induced tyrosine phosphorylation of the insulin receptor substrate is dependent on JAK1 expression in human fibrosarcoma cells. J. Immuno. 1997, 158: 1037-1040.
50. Sun XJ, Crimmins DL, Myers MG, Miralpeix M, White MF, Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol. Cell. Biol. 1993, 13: 7418-7428,
51. Dhand R, Hiles I, Panayotou G, Roche S, Fry MJ, Gout I, Totty NF, Truong O, Vicendo P, Yonezawa K, et al, PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J. 1994, 13:522-533.
52. Stephens LR, Jackson TR, Hawkins PT, Agonist-stimulated synthesis of phosphatidylinosito(3,4,5)-trisphosphate: a new intracellular signaling system? Biochim. Biophys. Acta. 1993, 1179: 27-75.
53. Franke TF, Kaplan DR, Cantley LC, Toker A, Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 1997, 275: 665-668.
54. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y, A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J. Bio. Chem. 1997, 272: 29911-29918.
55. Druronio V, Welham MJ, Abraham S, Dryden P, Schrader JW, p21ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating protein. Proc. Natl. Acad. Sci. USA. 1992, 89: 1587-1591.
56 Chardin P, Camonis JH, Gale NW, van Aelst L, Schlessinger J, Wigler MH, BarSagi D, Human Sos 1: a guanine nucleotide exchange factor for Ras that binds to GRB2. Science. 1993, 260: 1338-1343.
57. Denhardt DT, Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signaling. Bochem. J. 1996, 318:729-747.
58. Welham MJ, Learmonth L, Bone H, Schrader JW, Interleukin-13 signal transduction in lymphohemooietic cells. Similarities and differences in signal transduction with interleulin-4 and insulin. J. Biol. Chem. 1995, 270: 12286-12296.
59. Wery S, Letourneur M, Bertoglio J, Pierre J, Interleulin-4 induces activation of mitogen-activated protein kinase and phosphorylation of she in human keratinocytes. J. Biol. Chem. 1996 271: 8529-8532
60. Rozakis-Adcock M, McGlade J, Mbamalu G Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, et al, Association of the She and Grb2/Sem5 SH2-containning protein is implicated in activation of the Ras pathway by tyrosine kinases. Nature. 1992, 360: 689-692.
61. Ueno H, Sasaki K, Honda H, Nakamoto T, Yamagata T, Miyagawa K, Mitani K, Yazaki Y, Hirai H, c-Cb1 is tyrosinephosphorylated by interleukin-4 and enhances mitogenic and survival signals of interleukin-4 receptor by linking with the phosphatidylinostitol 3'-kinase pathway. Blood 1998, 91: 46-53.
62. Velazquez L, Fellous M, Stark GR, Pellegrini S, A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992 70: 313-322
63. Nakanishi K, Yoshida N, Kishimoto T, Akira S, Essential role of Stat-6 in IL-4 signalling. Nature. 1996, 380:627-630.
64. Mikita T, Campbell D, Wu PG Williamson K, Schindler U, Requirements for interleulin-4-induced gene expression and functional characterization of Stat-6. Mol. Cell. Biol. 1996, 16: 5811-20.
65. Schindler U, Wu P, Rothe M, Brasseur M, McKnight SL, Components of a Stat recognition code: evidence for two layers of molecular selectivity. Immunity. 1995, 2: 689-697.
66. Richter G, Hein G, Blakenstein T, Diamantstein T, The rat interleukin 4 receptor: coevolution of ligand and receptor. Cytokine. 1995, 7:237-241.
67. Ryan JJ, McReynolds LJ, Huang H, Nelms K, Paul WE, Characterization of a mobile Stat-6 motif in the human IL-4 receptor. J. Immunol. 1998, 161: 1811-1821.
68. Kim J, Reeves R, Rothman P, Boothby M, The non-histone chromosomal protein HMG-1(Y) contributes to repression of the immunoglobulin heavy chain germ-line epsilon RNA promoter. Eur. J. Immunol. 1995, 25: 789-808.
69. Muller M, Laxton C, Briscoe J, Schindler C, Improta T, Darnell JE Jr, Stark GR, Kerr IM, Complementation of a mutant cell line: central role of the 91kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways. EMBO J. 1993, 12:4221-4228.
70. Patel BKR, Pierce JH, LaRochelle WJ, Regulation of interleukin 4-mediated signaling by naturally occurring dominant negative and attenuated forms of human Stat-6. Proc. Natl. Acad. Sci. USA. 1998, 95: 172-177.
71. Delphin S, Stavnezer J, Characterization of an interleukin 4 (IL4) responsive region in the immunoglobulin heavy chain germline epsilon promoter: regulation by NG-IL-4 a C/EBP family member and NF-kappa B/p50. J. Exp. Med. 1995, 181: 181-192.
72. Wen Z, Zhong Z, Darnell JE Jr, Maximal activation of transcription by Stat 1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995, 82: 241-250.
73. Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S, Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science. 1995, 267: 1990-1994.
74. Urban JF Jr, Noben-Trauth N, Donaldson DD, Madden KB, Morris SC, Collins M, Finkelman FD, IL-13, IL-4Ralpha, and Stat-6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity. 1998, 8: 255-264.
75. Kaplan MH, Daniel C, Schindler U, Grusby MJ, Stat proteins control lymphocyte proliferation by regulating p27(Kip 1) expression. Mol. Cell. Biol. 1998, 18: 1996-2003.
76. Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA, The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N. Engl. J. Med. 1997, 337: 1720-1725.
77. Hou JZ, Schindler U, Henzel WJ, Ho TC, Brasseur M, McKnight SL, An interleukin-4-induced transcription factor-IL-4 Stat. Science. 1994, 265: 1701-1706.
78. D'Ambrosio D, Hippen KL, Minskoff SA, Mellman I, Pani G, Siminovitch KA, Cambier JC, Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1. Science. 1995, 268: 293-297.
79. Sun XJ, Pons S, Wang LM, Zhang Y, Yenush L, Burks D, Myers MG Jr, Glasheen E, Copeland NG, Jenkins NA, Pierce JH, White MF, The IRS-2-gene on murine chromosome 8 encodes a unique signaling adapter for insulin and cytokine action. Mol. Endocrinol. 1997, 11:251-262.
80. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE, Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998, 92: 441-450.
81. David M, Chen HE, Goelz S, Larner AC, Neel BG, Differential regulation of the alpha/beta interferonstimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 1995, 15: 7050-7058.
82. Damen JE, Liiu L, Rosten P, Humphries RK, Jefferson AB, Majerus PW, Krystal G, The 145kDa protein induced to associate with She by multiple cytokines is an inostiol tetraphosphate and phosphatidylinositol 3,4,50triphosphate 5-phosphatase. Proc. Natl.Acad. Sci, USA 1996, 93: 1689-1693.
83. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A, A new protein containing an SH2 domain that inhibits JAK kinase. Nature. 1997, 387: 921-924.
84. Boguski MS, McCormick F, Proteins regulating Ras and its relatives. Nature. 1993, 366 643-654.
85. Yamanashi Y, Baltimore D, Identification of the Abl- and rasGAP-associated 62kDa protein as a docking protein, Dok. Cell. 1997, 88: 205-211.
86. Meier H, Myers DD, Huebner RJ, Genetic control by the hr-locus of susceptibility and resistance to leukemia. Proc. Natl. Acad. Sci. 1963, 63: 759-766.
87. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM, Maintenance of human T cell anergy: blocking of Ⅱ-2 gene transcription by activated Rapl. Science. 1997, 278: 124-128.
88. Noben-Trauth N, Shultz L. D, Brombacher F, Urban J. F, Gu H, Paul WE, An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc. Natl. Acad. Sci. USA. 1997, 94: 10838-10843.
89. Schulte T, Kurrle R, Rollinghoff M, Gessner A, Molecular characterization and functional analysis of murine interleukin 4 receptor allotypes. J. Exp. Med. 1997, 186: 1419-1429.
90. Hackstin H, Kluter H, Fricke L, Hoyer J, Bein G, The IL-4 receptor alpha-chain variant Q576R is strongly associated with decreased kidney allograft survival. Tissue. Antigens. 1999, 54: 471-477.
91. Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokuchi K, Imoto N, Nakahara S, Matsui A, Hamaguchi H, Lack of association of atopy/asthma and the interleukin-4 reeptor alpha gene in Japanese. Clin. Exp. Allergy. 1999, 29: 228-233.
92. Dastot F, Sobrier ML, Duquesnoy P, Duriez B, Goossens M, Amselem S, Alternatively spliced forms in the cytoplasmic domain of the human growth hormone (GH) receptor regulate its ability to generate a soluble GH-binding protein. Proc. Natl. Acad. Sci. USA. 1996, 93: 10723-10728.
93. Skoda RC, Seldin DS, Chiang MK, Peichel CL, Leder P, Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBOJ. 1993, 12: 2645-2653.
94. Kruse S, Forster J, Kuehr J, Deichmann KA. Characterization of the membrane-bound and a soluble form of human IL-4 receptor α produced by alternative splicing. International,. Immunology. 1999, 11: 1965-1969.
95. Jung T, Schrader N, Hellwig M, Enssle KH, Neumann C. Soulble human interleukin-4 receptor is produced by activated T cells under the control of metalloproteinases, Int. Arch. Allergy. Immunol. 1999, 119: 23-30.
96. Baumann G., Shaw MA, Buchanan TA, In vivo kinetics of a covalent growth hormone-binding protein complex. Metabolism. 1989, 38: 330-333.
97. Ku H, Hirayama F, Kato T, Miyazaki H, Aritomi M, Ota Y, D'Andrea AD, Lyman SD,??Ogawa M, Soluble thrombopoietin receptor and granulocyte colony-stimulating factor receptor directly stimulate proliferation of primitive hematopoietic progenitors of mice in synergy with steel factor or the ligand of Flt3/Flk2. Blood 1996, 88: 4124-4131.
98. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D, Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 1992, 175: 323-329.
99. Rose-John S, Ehlers M, Grotzinger J, Mullberg J, The soluble interleukin-6 receptor. Ann. NY Acad. Sci. 1995, 762: 207-220.
100. Fernandez-Botran R, Chilton PM, Ma Y, Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy. Adv. Immunol. 1996, 63: 269-336.
101. Heaney ML, Golde DW, Soluble receptors in human disease. J. Leukoc. Biol. 1998, 64: 135-146.
102. Fernanadez-Botran R, Vitetta ES, A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. Proc. Natl. Acad. Sci. USA. 1990, 87: 4202-4206.
103. Sang DK, Ouma JH, John CC, Whalen CC, King CL, Mahmoud AA, Heinzel FP, Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. J. Infect. Dis. 1999, 179: 743-746.
104. Chilton PM, Fernandez-Botran R, Regulation of the expression of the soluble and membrane forms of the murine IL-4 receptor. Cell. Immunol. 1997, 180: 104-115.
105. Garrone P, Djossou O, Galizzi JP, Banchereau J, A recombinant extracellular domain of the human interleukin 4 receptor inhibits the biological effects of interleukin 4 on T and Blymphocytes. Eur. J. Immunol. 1991, 21: 1365-1369.
106. Maliszewski CR, Sato TA, Vanden Bos T, Waugh S, Dower SK, Slack J, Beckmann MP, Grabstein KH, Cytokine receptors and B cell functions. I. recombi.nant soluble receptors specifically inhibit IL-1- and IL-4-induced B cell activities in vitro. J. Immuno. 1990, 144: 3028-3033.
107. Fernandez-Botran R, Vitetta ES, Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J. Exp. Med. 1991, 174: 673-681.
108. Gessner A, Schroppel L, Will A, Enssle KH Lauffer L, Rollinghoff M, Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous Leishmaniasis. Infec. Immun. 1994, 62: 4112-4117.
109. Puccetti P, Mencacci A, Cenci E, Spaccapelo R, Mosci P, Enssle KH, Romani L, Bistiohi F, Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J. Inect. Dis. 1994, 169: 1325-1331.
110. Renz H, Enssle K, Lauffer L, Kurrle R, Gelfand E. W, Inhibition of allergen-induced IgE and IgG1 production by soluble IL-4 receptor. Int. Arch. Allergy. Immunol. 1995, 106: 46-54.
111. Renz H, Bradley K, Enssle K, Loader JE, Larsenx EW, Gelfand EW, Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor. Int. Arch. Allergy. Immuno. 1996, 109: 167-176.112. Kobayashi H, Kobayashi M, Utsunomiya T, Hemdon DN, Pollard RB, Susuki F, Therapeutic protective effects of IL-12 combined with soluble IL-4 receptor against established infections of herpes simplex virus type 1 in thermally injured mice. J. Immunol. 1999, 162: 7148-7154.
113. Kay AB. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 2001, 344: 30-37.
114. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J. Clin. Invest. 1999, 104: 1001-1006.
115. Vogel G. New clues to asthma therapies. Science. 1997, 276: 1643-1646.
116. Barnes PJ. Cytokine-directed therapies for asthma. J. Allergy. Clin. Immunol. 2001, 108: S72-S76.
117. Sano Y, Suzuki N, Yamada H, To Y, Ogawa C, Ohta K, Adachi M. Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma. J. Allergy. Clin. Immunol. 2003, 111: 958-966.
118. Harbinson PL, MacLeod D, Hawksworth R, O' Toole S, Sullivan PJ, Heath P, Kilfeather S, Page CP, Costello J, Holgate ST, Lee TH. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur: Respir. J. 1997, 10: 1008-1014.
119. O' Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J. Allergy. Clin. Immunol. 2001, 108: 503-508.
120. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil' s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care. Med. 2003, 167: 199-204.
121. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore J-B, Agosti JM. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy. Clin. Immunol. 2001, 107: 963-970.
122. Barnes PJ. Current Therapy for Asthma. Hansel TT, Barnes PJ(eds): New Drugs for Asthma, Allergy and COPD. Prog. Respir. Resr: 2001, 31: 6-10.
123. Borish L, Agosti JM. Interleukin-4 Antagonism. Hansel TT, Barnes PJ(eds): New Drugs for Asthma, Allergy and COPD. Prog. Respir. Res. 2001, 31: 256-259.
124. Vella A, Teague TK, Ihle J, Kappler J, Marrack P. Interleukin 4(IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-4. J. Exp. Med. 1997, 186: 325-330.
125. Evans TJ, Moyes D, Carpenter A, Martin R, Cohen J, Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptore-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J. Exp. Med. 1994, 180: 2173-2179.
126. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garriso L. Interleukin-4 receptor in moderate atopic asthma: A phase Ⅰ/Ⅱ randomized, placebo-controlled trial. Am. J. Respir. Crit. Care. Med. 1999, 160: 1816-1823.
127. Pollock HW, Ebert CS, Dubin MG, White DR, Prazma J, Pillsbury HC 3rd. The role of soluble interleukin-4 receptor and interleukin-5 ntibody in preventing late-phase??allergy-induced eustachian tube dysfunction. Otolaryngol. Head. Neck. Surg. 2002, 127: 169-176.
128. Katakura T, Kobayashi M, Fujita K, Herndon DN, Pollard RB, Suzuki F, A Combination Therapy Using IL-12 and Soluble IL-4 Receptor on Herpes Simplex Virus Type 1 Infection in a Human-SCID Chimera Model of Thermal Injury. Clin. Immunol. 2002, 105: 363-370.
129. Kobayashi M, Takahashi H, Herndon DN, Pollard RB, Suzuki F. Effect of a combination therapy between IL-12 and soluble IL-4 receptor (slL-4R) on Candida albicans and herpes simplex vierus type 1 infections in thermally injured mice. Can. J. Microbiol. 2002, 48: 886-894.